《金融时报》记者注意到，中小银行为吸引更多储蓄资源，在存款利率设置上通常要略高于全国性银行。在本次调整后，部分城商行定期存款挂牌利率与 绝大多数股份行保持一致，整体的利率优势已不再明显。 紧跟全国性银行的步伐，各家城商行正在陆续下调存款挂牌利率。 记者从北京银行（601169）官网了解到，自5月27日起，该行已执行新的存款挂牌利率。调整后，该行一年期、二年期、三年期、五年期整存整取定期存 款挂牌利率分别调整为1.15%、1.20%、1.30%、1.35%，与光大银行（601818）、中信银行（601998）等多家股份制银行存款挂牌利率保持一致。 | 人民币储蓄存款利率表 (2025年5月27日起执行) | | | --- | --- | | 各项存款 | 储蓄存款利率(%) | | 一、活期存款 | 0.05 | | 二、定期存款 | | | (一) 整存整取 | | | 三个月 | 0. 70 | | 半年 | 0. 95 | | 一年 | 1. 15 | | 二年 | 1. 20 | | 三年 | 1. 30 | | 五年 | 1. 35 | 自5月26日起，江苏银行（600919）也调整了人民币存款挂牌 ...

Investment Rating - The report indicates a positive outlook for the banking sector, suggesting that certain stocks may have alpha potential due to policy catalysts and a cyclical recovery [4]. Core Insights - Multiple banks have lowered their deposit rates, with the one-year and five-year Loan Prime Rate (LPR) reduced by 10 basis points on May 20, 2025. This trend reflects a broader market-driven decline in deposit costs [1][2]. - The average deposit cost rate for China Merchants Bank decreased significantly by 25 basis points to 1.29% in Q1 2025, indicating a trend of improving deposit costs across the sector [1]. - The report highlights that banks like Chongqing Bank, Minsheng Bank, and CITIC Bank have substantial room for further deposit cost reductions, suggesting a favorable environment for banks to optimize their funding costs [2]. Summary by Sections Section 1: Focus of the Week - Several banks have adjusted their deposit rates downward, with over half of listed banks participating in this trend by May 24, 2025 [1]. - The report notes that the average deposit cost rate for China Merchants Bank has shown improvement since Q2 2024, aligning with previous forecasts of enhanced cost reduction in liabilities [1]. Section 2: Sector Perspective - The banking sector is expected to benefit from expansionary policies aimed at stabilizing the economy, with specific banks like Ningbo Bank, Postal Savings Bank, and China Merchants Bank highlighted as potential investment opportunities [4]. - The report emphasizes that the cyclical recovery may take time, but the ongoing interest rate cuts could sustain the dividend strategy for banks like Shanghai Bank and Jiangsu Bank [4]. Section 3: Key Data Tracking - The report tracks various financial metrics, including the issuance of interbank certificates and the average rates for different types of bank notes, indicating a dynamic market environment [9][8]. - It also notes the increase in the proportion of deposits with a remaining maturity of less than one year, which rose by 3 percentage points to 37.4% by the end of 2024, suggesting a trend towards concentrated deposit maturities [2][16].

Group 1: Management Changes - Recent management changes at Shanghai Bank include the appointment of Gu Jianzhong as the new chairman, while Vice President Wang Ming is set to take over as the president of Shanghai Rural Commercial Bank [2][11] - Gu Jianzhong has a long history with Shanghai Bank, having held various positions since joining in 1997, and he emphasizes the importance of talent as the primary resource for commercial banks [11][13] Group 2: Asset Quality and Non-Performing Loans - Shanghai Bank has seen a decline in its non-performing loan (NPL) ratio, which fell to 1.18% by the end of 2024, marking a decrease for two consecutive years [2][7] - The bank has implemented over 100 billion yuan in NPL write-offs over the past three years, focusing on sectors like real estate and consumer loans where NPLs were concentrated [3][7] - The bank's NPLs peaked at 3.05% in 2021, with a balance of 47.6 billion yuan, but have since improved due to aggressive risk management strategies [6][7] Group 3: Financial Performance - Shanghai Bank's revenue, net profit, and total assets have seen a decline in rankings among city commercial banks, dropping to fourth in net profit and total assets by 2024 [8][9] - In 2024, the bank reported a revenue of 52.99 billion yuan and a net profit of 23.56 billion yuan, with year-on-year growth rates of 4.8% and 4.4%, respectively [9][10] - Despite recent challenges, the bank's stock price has increased by over 110% since 2024, attributed to the improvement in NPL ratios and increased dividend payouts [10] Group 4: Strategic Focus - Gu Jianzhong highlighted the bank's strategic focus on key areas such as technology innovation, green finance, inclusive finance, and manufacturing to enhance competitiveness [2][13] - The bank aims to strengthen its organizational structure, product innovation, customer service, and distribution channels as part of its future development strategy [13]

Core Viewpoint - The article highlights the active performance of the defense and military industry, with significant stock price increases in related companies, driven by geopolitical tensions and government policies supporting military spending [20][21]. Defense and Military Industry - The defense and military sector showed strong performance, with stocks like Guoke Tiancai rising by 20%, and several others reaching their daily limit [4][7]. - The U.S. announcement of a $175 billion investment in missile defense systems has raised concerns about escalating military competition, which may benefit the defense sector in China [19]. - China's recent white paper on national security emphasizes the importance of maintaining territorial integrity and enhancing military capabilities, which supports the growth of the defense industry [20]. Banking Sector - The banking sector experienced a collective rise, with banks like Qingdao Bank and Shanghai Bank reaching new all-time highs [23][24]. - Recent adjustments in the Loan Prime Rate (LPR) and deposit rates are expected to impact the banking sector positively, with a focus on stabilizing growth and improving asset quality [26]. - Analysts predict that the banking sector will benefit from a series of financial policies aimed at supporting economic recovery, leading to a potential performance turnaround [26].

Core Viewpoint - The article highlights the implementation of cross-border financing facilitation policies in Shanghai, aimed at easing the financial pressures on technology-oriented enterprises, particularly in the biotech sector, by expanding their access to foreign debt financing [1][2][3]. Group 1: Cross-Border Financing Policies - The State Administration of Foreign Exchange (SAFE) Shanghai Branch has included technology-oriented SMEs in the cross-border financing facilitation pilot program, allowing eligible high-tech and specialized enterprises to borrow foreign debt up to $10 million based on actual operational needs [3]. - Since the expansion of this policy in 2024, eight technology companies in Shanghai have completed nine pilot transactions, accelerating their innovation and development [3]. - The facilitation of foreign debt registration has led to nearly 600 registrations, including over 80 for technology companies, significantly reducing operational and communication costs for these firms [5][6]. Group 2: Financial Support for Technology Companies - A specific biotech company received a foreign debt quota of 11 million RMB within two weeks of applying for the facilitation policy, demonstrating the efficiency of the new measures [2]. - The SAFE Shanghai Branch has also streamlined the process for non-financial enterprises to list abroad and for foreign employees to participate in domestic equity incentives, enhancing access to international capital markets [3]. Group 3: QFLP Pilot Program - The Qualified Foreign Limited Partner (QFLP) pilot program has been expanded to cover the entire Shanghai area, allowing foreign investors to participate in domestic equity investments more easily [4]. - The QFLP program primarily targets high-tech sectors such as biomedicine, information technology, and new materials, with over 40% of investments directed towards high-tech fields [4]. Group 4: High-Level Open Policies - Starting in 2024, several high-level open policies have been extended to the entire Shanghai area, effectively lowering cross-border financing costs for technology companies [5]. - By the end of March, 39 banks and 828 quality enterprises participated in the high-level open pilot, processing 374,100 facilitation transactions totaling $212.45 billion, with specialized enterprises accounting for 32 million [6]. Group 5: Cross-Border Fund Management - The SAFE Shanghai Branch is enhancing the management of cross-border fund operations for multinational companies, allowing for better resource allocation and efficiency in fund usage [9][10]. - The introduction of the "3.0 version" of the cross-border fund pool policy aims to facilitate the centralized management of both domestic and foreign currency funds for multinational corporations [9][10].

Core Viewpoint - The recent trend of financial institutions, including banks and insurance companies, to abolish supervisory boards reflects a significant reform in corporate governance, driven by changes in the Company Law of the People's Republic of China [1][6][12]. Group 1: Abolishment of Supervisory Boards - Changsha Bank has decided to abolish its supervisory board, transferring its functions to the audit committee of the board of directors [1]. - Many financial institutions, including major state-owned banks and insurance companies, are following suit, indicating a broader shift in governance practices [1][6]. - The new Company Law allows limited liability companies to establish an audit committee within the board of directors to perform the functions of a supervisory board, thus eliminating the need for a separate supervisory board [6][9]. Group 2: Regulatory Changes and Implications - The National Financial Regulatory Administration has issued new regulations that allow trust companies to set up audit committees within their boards, further promoting the idea of eliminating supervisory boards [2][6]. - The changes aim to enhance operational efficiency by reducing redundancy in oversight functions, as the roles of supervisory boards and audit committees often overlap [2][8]. - The flexibility provided by the new governance structure is expected to lead to more tailored governance models that suit the specific needs of different financial institutions [9][10]. Group 3: Impact on Corporate Governance - The shift to a single-tier governance model allows boards to exercise oversight more directly, potentially improving decision-making efficiency in a rapidly changing financial environment [9][10]. - Smaller financial institutions may benefit from reduced operational costs by not having a supervisory board, while larger institutions may require more complex oversight mechanisms [9][10]. - The transition to audit committees taking on supervisory roles is seen as a way to innovate governance structures and improve compliance management [10][12]. Group 4: Concerns and Future Considerations - There are concerns regarding the effectiveness of audit committees in fulfilling the oversight roles traditionally held by supervisory boards, particularly regarding potential conflicts of interest [11][12]. - Experts suggest that while the new structure may reduce costs, it is crucial to ensure that adequate checks and balances remain in place to maintain effective governance [11][12]. - Future modifications to the Company Law may be necessary to address the evolving needs of corporate governance in the financial sector [12].

Group 1 - Huiyu Pharmaceutical's subsidiary received drug registration certificate for Carboxymethyl Sodium Injection, which is used for treating bleeding diseases in various medical fields [1] - Baihe Co., Ltd. announced a plan for a director to reduce holdings by up to 424,000 shares, representing 0.6625% of the total share capital [1] - Kingood Co., Ltd. received a notification from a global leading automaker for a wheel project, expected to start mass production in 2026 with a lifecycle of 10 years [1][2] Group 2 - Wanhua Chemical plans to repurchase shares worth between 300 million and 500 million yuan, with a maximum repurchase price of 99.36 yuan per share [2] - Warner Pharmaceutical's subsidiary received approval for Acetylcysteine raw material drug, primarily used for treating respiratory diseases [3] - ST Mingcheng plans to publicly transfer 45% equity of its subsidiary, aiming to optimize asset structure [4] Group 3 - Qixia Construction announced a plan to reduce up to 31.5 million shares, accounting for 3% of total share capital [5][6] - Zhejiang Rongtai intends to invest 20 million yuan to establish a wholly-owned subsidiary focused on intelligent robotics [7] - Yuandong Biological received drug registration for Chloral Hydrate Enema, used for sedation and seizure control in children [9] Group 4 - Jiemai Technology's subsidiary signed a strategic cooperation agreement with a solid-state battery company to produce high-safety composite conductive materials [10] - Xianju Pharmaceutical received drug registration for Progesterone Soft Capsules, used for treating functional disorders due to luteal deficiency [11] - Lanhua Kecai's subsidiary reported a temporary production halt, with the resumption date yet to be determined [13] Group 5 - Sinopharm Modern's subsidiary received drug registration for Tocilizumab Tablets, used for treating rheumatoid arthritis and other conditions [15] - Shanghai Bank announced the resignation of its vice president due to organizational adjustments [17] - Shanghai Pharmaceutical's Ephedrine Injection passed the consistency evaluation for generic drugs [19] Group 6 - Rundu Co., Ltd. received drug registration for Amlodipine and Olmesartan Tablets, aimed at treating hypertension [21] - Zhong'an Technology announced that 61 million shares held by its controlling shareholder will be auctioned [23] - Shanghai Washba plans to purchase patent assets and establish two subsidiaries focused on hydrogen energy and solid-state battery technologies [25] Group 7 - Nuo Cheng Jianhua's new drug Tafasitamab received approval for treating relapsed/refractory diffuse large B-cell lymphoma [26] - Benli Technology plans to use up to 200 million yuan of idle funds for cash management and financial investments [28] - Taiji Co., Ltd. intends to use 60 million yuan of idle funds to purchase financial products [29] Group 8 - Haishi Co. announced that its innovative drug Anreke Fen Injection received drug registration for treating postoperative pain [32] - Yulong Co. will have its stock delisted on May 27, 2025, following a decision by the Shanghai Stock Exchange [36] - Weifu High-Tech plans to establish a joint venture with Shanghai Baolong Automotive Technology [38] Group 9 - Xichang Electric Power expects a net profit reduction of approximately 5.4 million yuan due to adjustments in the time-of-use electricity pricing mechanism [39] - Alter signed a contract worth 6.8 billion yen for the development and procurement of large truck EV kits [41] - Zhonglian Heavy Industry plans to acquire controlling stakes in its financing leasing subsidiary through public bidding [42] Group 10 - Sanyou Medical's executive plans to reduce holdings by up to 1.44% of the company's shares [43] - Hangyang Co. plans to establish a subsidiary for large modular cryogenic equipment manufacturing with an estimated investment of 557 million yuan [44] - FAW Fuwi received a notification for a dashboard project from a well-known new energy brand, with total sales expected to reach 1.06 billion yuan [45]

Group 1 - The announcement details the resignation of Mr. Wang Ming from the position of Vice President of Shanghai Bank due to organizational adjustments [3] - The board of directors approved Mr. Wang's resignation with a unanimous vote of 16 in favor, effective immediately upon the board's decision [3] - Mr. Wang will continue to fulfill his commitment to lock up shares of Shanghai Bank for two years after his purchase, despite his resignation [3] Group 2 - Mr. Wang has confirmed that there are no disagreements with the board and no other matters to notify shareholders or creditors [3] - The board expressed gratitude for Mr. Wang's contributions during his tenure [3]

上海银行股份有限公司 关于 2025 年第一期科技创新债券发行完毕的公告 上海银行股份有限公司（以下简称"公司"）董事会及全体董事保证本公告 内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担法律责任。 经中国人民银行核准，公司在全国银行间债券市场发行"上海银行股份有限 公司 2025 年第一期科技创新债券"（以下简称"本期债券"），并在中央国债登记 结算有限责任公司完成债券的登记、托管。 本期债券于 2025 年 5 月 16 日簿记建档，并于 2025 年 5 月 20 日发行完毕。 本期债券发行规模为人民币 50 亿元，为 3 年期固定利率品种，票面利率为 1.67%。 证券代码：601229 证券简称：上海银行 公告编号：临 2025-028 优先股代码：360029 优先股简称：上银优 1 可转债代码：113042 可转债简称：上银转债 上海银行股份有限公司董事会 2025 年 5 月 22 日 1 本期债券募集资金将用于发放科技贷款、发放科技相关产业贷款、投资科技 创新企业发行的债券等，专项支持科技创新领域业务。 特此公告。 ...

证券代码：601229 证券简称：上海银行 公告编号：临2025-027 优先股代码：360029 优先股简称：上银优1 可转债代码：113042 可转债简称：上银转债 上海银行股份有限公司 关于副行长离任的公告 上海银行股份有限公司（以下简称"公司"或"上海银行"）董事会及全体 董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内 容的真实性、准确性和完整性承担法律责任。 二、离任对公司的影响 近日，公司董事会收到汪明先生辞呈。因组织工作调动，汪明先生辞去公司 副行长职务。公司于 2025 年 5 月 21 日以视频接入方式召开董事会 2025 年第六 次会议，会议以 16 票同意、0 票反对、0 票弃权审议通过了《关于汪明先生辞任 副行长的议案》，同意汪明先生辞任公司副行长职务，并自董事会审议通过之日 起生效。汪明先生同时辞去公司总法律顾问职务，并不再担任公司任何职务。 2 汪明先生确认其与公司董事会无不同意见，亦没有任何其他事项需要通知公 1 一、高级管理人员离任情况 姓名 离任职务 离任时间 原定任期 到期日 离任原因 是否继续在上 市公司及其控 股子公司任职 是否存在 未履行完 毕 ...